Study of the in vitro and in vivo antileishmanial activities of nimodipine in susceptible BALB/c mice | Zendy

Mahmoudreza Jaafari | Zendy; Reza Azadi | Zendy; Ghazal Alipour-Talesh | Zendy; Mohammad Javad Yazdanpanah | Zendy; SeyedehHoda Alavizadeh | Zendy; Masoud Maleki | Zendy; Mahnaz Banihashemi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Study of the in vitro and in vivo antileishmanial activities of nimodipine in susceptible BALB/c mice

Author(s) -

Mahmoudreza Jaafari,

Reza Azadi,

Ghazal Alipour-Talesh,

Mohammad Javad Yazdanpanah,

SeyedehHoda Alavizadeh,

Masoud Maleki,

Mahnaz Banihashemi

Publication year - 2020

Publication title -

journal of vector borne diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.581

H-Index - 41

ISSN - 0972-9062

DOI - 10.4103/0972-9062.308805

Subject(s) - nimodipine , meglumine antimoniate , pharmacology , amphotericin b , in vivo , amastigote , medicine , chemistry , leishmania , cutaneous leishmaniasis , leishmaniasis , calcium , immunology , biology , antifungal , microbiology and biotechnology , parasite hosting , dermatology , world wide web , computer science

Pentavalent antimonials are the standard treatment for cutaneous leishmaniasis (CL), however, treatment failures are frequent. Nimodipine, a calcium channel blocker is known to show promising antiprotozoal effects. Here, we investigated the antileishmanial effect of Nimodipine in both in vitro and in vivo BALB/c mice model of CL. We also compared the in vivo effect with amphotericin B and meglumine antimoniate in the experimental CL mice model.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research